Daver, N. G., Wang, E. S., Sweet, K. L., Montesinos, P., Erba, H. P., DeAngelo, D. J., … Zweidler-McKay, P. A. (2020). A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Daver, Naval Guastad, Eunice S. Wang, Kendra L. Sweet, Pau Montesinos, Harry Paul Erba, Daniel J. DeAngelo, Callum Mortimer Sloss, Jiuzhou Wang, Kara E. Malcolm, and Patrick A. Zweidler-McKay. “A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Daver NG, Wang ES, Sweet KL, Montesinos P, Erba HP, DeAngelo DJ, et al. A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Daver, Naval Guastad, et al. “A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Daver NG, Wang ES, Sweet KL, Montesinos P, Erba HP, DeAngelo DJ, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PA. A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2020.